(SVRA) Savara - Ratings and Ratios

Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company specializing in the development of therapies for rare respiratory diseases. The companys lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 clinical trials for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare and life-threatening lung disorder. Savara is headquartered in Langhorne, Pennsylvania, and focuses on addressing unmet medical needs in pulmonary diseases. Web URL: https://www.savarapharma.com.

Based on the provided data, here is a 3-month forecast for Savara Inc. (SVRA):

Average Volume 20d: 698,482 shares. Last Price: $2.46. SMA 20: $2.74, SMA 50: $2.90, SMA 200: $3.77. ATR: 0.15. Market Cap: $461.66M. P/E: 0.00, P/E Forward: 0.00. P/B: 2.31. RoE: -41.60%. The stock is currently trading below its SMA 20, SMA 50, and SMA 200, indicating bearish momentum. Resistance levels at $4.8, $4.2, $3.7, and $3.1 may act as barriers to upward movement. The ATR of 0.15 suggests moderate volatility. Fundamentally, the companys negative RoE (-41.60%) reflects ongoing losses, typical for a clinical-stage biotech firm. The P/B ratio of 2.31 indicates that the market values the companys assets higher than their book value, potentially reflecting optimism about its pipeline. Over the next 3 months, SVRA is likely to remain under pressure due to its current price trend and resistance levels. However, any positive developments in its Phase 3 trials for molgramostim could act as a catalyst for upside movement. The stock may consolidate near its current levels, with potential downside risks tied to broader market conditions and clinical trial outcomes.